KLTO - PRISM Mid-Day Movers: Clinical Updates and Contract Wins Drive Index Action
2025-05-14 14:31:18 ET
Incannex Rockets 860% on Drug Progress for Sleep Apnea
Incannex Healthcare Inc. ( IXHL ) catapulted over 860% to lead the PRISM Emerging Psychedelics Index after announcing it had completed patient dosing in the Phase 2 portion of its pivotal Phase 2/3 study for IHL-42X , an investigational once-daily oral treatment for obstructive sleep apnea (OSA). The company expects topline data in July and is preparing for an end-of-Phase 2 meeting with the FDA to discuss regulatory pathways. Unlike traditional devices like CPAP, IHL-42X targets OSA's underlying physiology, potentially offering a first-in-class pharmacologic alternative for millions affected by the condition.
Although IHL-42X is not a psychedelic drug, IXHL's pipeline includes a drug that combines synthetic CBD and hydroxychloroquine, now in Phase 2 trials for treating rheumatoid arthritis and a synthetic psilocybin drug being tested with therapy to treat adults with generalized anxiety disorder.
Creative Realities Climbs 19% on ARR Growth and Strategic Win
Creative Realities Inc. ( CREX ) rose nearly 19%, boosting the PRISM Emerging AdTech & Media Index after reporting Q1 results and landing a major new contract . Despite a year-over-year revenue decline due to deployment timing, the company highlighted strong annual recurring revenue growth, now at $17.3 million, and a recent contract win with a national restaurant chain to revamp menu board systems. Adjusted EBITDA came in at $0.5 million, with the company positioning itself for improved results in the second half of 2025.
Other PRISM Movers:
- Klotho Neuroscience Inc. ( KLTO ): +166.46%
- Humacyte Inc. ( HUMA ): +13.59%
- Knightscope Inc. ( KSCP ): +14.41%
- WW International ( WW ): -12.88%
The post PRISM Mid-Day Movers: Clinical Updates and Contract Wins Drive Index Action appeared first on PRISM MarketView .
COMTEX_465506831/2927/2025-05-14T13:31:18